Dashboard
Poor long term growth as Operating profit has grown by an annual rate -5.46% of over the last 5 years
- PAT(Q) At Rs 28.37 cr has Fallen at -57.8% (vs previous 4Q average)
- NET SALES(Q) At Rs 473.03 cr has Fallen at -10.7% (vs previous 4Q average)
- DEBTORS TURNOVER RATIO(HY) Lowest at 1.26 times
With ROE of 9.3, it has a Expensive valuation with a 2.8 Price to Book Value
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
INR 6,705 Cr (Small Cap)
30.00
34
0.00%
-0.17
9.27%
2.78
Total Returns (Price + Dividend) 
Latest dividend: 5 per share ex-dividend date: Nov-22-2024
Risk Adjusted Returns v/s 
Returns Beta
News

FDC Sees Revision in Market Assessment Amidst Challenging Financial Trends
FDC, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation, reflecting shifts in its financial and technical outlook. This adjustment comes amid a backdrop of subdued operational performance and valuation concerns, prompting investors to reassess the stock’s position within its sector.
Read MoreIs FDC technically bullish or bearish?
As of 18 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for FDC is bearish with a moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish signal from Bollinger Bands on both weekly and monthly timeframes. The KST is also bearish on the weekly, reinforcing the negative outlook. Although the OBV shows a bullish signal on the monthly, it does not outweigh the overall bearish indicators....
Read More
FDC Technical Momentum Shifts Amid Bearish Indicators in Pharmaceuticals Sector
FDC, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical parameters, reflecting a change in price momentum and market sentiment. Recent data reveals a transition from mildly bearish to bearish technical trends, with several indicators signalling adjustments in the stock’s evaluation.
Read More Announcements 
FDC Limited - Clarification - Financial Results
14-Nov-2019 | Source : NSEFDC Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
FDC Limited - Updates
18-Oct-2019 | Source : NSEFDC Limited has informed the Exchange regarding 'Acquisition of Registered Trademark/ Brand "ENTEROPLUS" from GlaxoSmithKline Pharmaceuticals Limited (GSK)'.
FDC Limited - Updates
16-Oct-2019 | Source : NSEFDC Limited has informed the Exchange regarding 'Certificate in terms of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 ( said regulations ) on behalf of FDC Limited ( the Company ) for the quarter ended on September 30, 2019'.'.
Corporate Actions 
No Upcoming Board Meetings
FDC Ltd has declared 500% dividend, ex-date: 22 Nov 24
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 9 Schemes (6.63%)
Held by 100 FIIs (2.43%)
Nomita R Chandavarkar (22.67%)
Icici Prudential Smallcap Fund (3.59%)
16.4%
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is -27.05% vs 31.82% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is -76.62% vs 213.81% in Jun 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -2.66% vs 12.65% in Sep 2024
Growth in half year ended Sep 2025 is -21.65% vs 6.33% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'24
YoY Growth in nine months ended Dec 2024 is 9.14% vs 9.78% in Dec 2023
YoY Growth in nine months ended Dec 2024 is -11.90% vs 58.54% in Dec 2023
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 8.50% vs 8.92% in Mar 2024
YoY Growth in year ended Mar 2025 is -12.59% vs 57.30% in Mar 2024






